Calponin 3, Acidic (CNN3) (C-Term) Peptide
CNN3
Reactivity: Human
Host: Synthetic
BP, WB
-
- Target See all CNN3 products
- CNN3 (Calponin 3, Acidic (CNN3))
- Protein Region
- C-Term
- Origin
- Human
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB)
- Sequence
- NGLVLWTVFR SSREKRRSAD IFIASLAVAD LTFVVTLPLW ATYTYRDYDW
- Characteristics
- This is a synthetic peptide designed for use in combination with anti-CNN3 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Purification
- Purified
-
-
- Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Concentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Handling Advice
- Avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- CNN3 (Calponin 3, Acidic (CNN3))
- Background
-
This gene encodes a member of the G protein-coupled receptor gene family. The encoded protein is related to the angiotensin receptor, but is actually an apelin receptor that inhibits adenylate cyclase activity and plays a counter-regulatory role against the pressure action of angiotensin II by exerting hypertensive effect. It functions in the cardiovascular and central nervous systems, in glucose metabolism, in embryonic and tumor angiogenesis and as a human immunodeficiency virus (HIV-1) coreceptor. Two transcript variants resulting from alternative splicing have been identified.
Alias Symbols: -
Protein Interaction Partner: APLN
Protein Size: 380 - Molecular Weight
- 43 kDa
- Gene ID
- 1266
- NCBI Accession
- NM_001839, NP_001830
- UniProt
- Q15417
-
You are here:
